Cargando…
FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model
BACKGROUND: Malignant mesothelioma (MM) is a very aggressive type of cancer, with a dismal prognosis and inherent resistance to chemotherapeutics. Development and evaluation of new therapeutic approaches is highly needed. Immunosuppressant FTY720, approved for multiple sclerosis treatment, has recen...
Autores principales: | Szymiczek, Agata, Pastorino, Sandra, Larson, David, Tanji, Mika, Pellegrini, Laura, Xue, Jiaming, Li, Shuangjing, Giorgi, Carlotta, Pinton, Paolo, Takinishi, Yasutaka, Pass, Harvey I., Furuya, Hideki, Gaudino, Giovanni, Napolitano, Andrea, Carbone, Michele, Yang, Haining |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5353897/ https://www.ncbi.nlm.nih.gov/pubmed/28298211 http://dx.doi.org/10.1186/s12967-017-1158-z |
Ejemplares similares
-
FTY720-derivatives do not induce FTY720-like lymphopenia
por: Segura-Ulate, Ismael, et al.
Publicado: (2017) -
Inhibition of the spindle assembly checkpoint kinase Mps-1 as a novel therapeutic strategy in malignant mesothelioma
por: Szymiczek, Agata, et al.
Publicado: (2017) -
Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma
por: Carbone, Michele, et al.
Publicado: (2016) -
FTY720 attenuates excitotoxicity and neuroinflammation
por: Cipriani, Raffaela, et al.
Publicado: (2015) -
HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma
por: Pellegrini, Laura, et al.
Publicado: (2017)